Endoglin in Amniotic Fluid as a Risk Factor for the Subsequent Development of Bronchopulmonary Dysplasia
Article first published online: 24 DEC 2012
Published 2012. This article is a U.S. Government work and is in the public domain in the USA.
American Journal of Reproductive Immunology
Volume 69, Issue 2, pages 105–123, February 2013
How to Cite
Endoglin in amniotic fluid as a risk factor for the subsequent development of bronchopulmonary dysplasia.Am J Reprod Immunol 2013; 69: 105–123, , , , , , , , .
- Issue published online: 8 JAN 2013
- Article first published online: 24 DEC 2012
- Manuscript Accepted: 23 OCT 2012
- Manuscript Received: 9 OCT 2012
- National Institute of Child Health and Human Development
- Perinatology Research Branch, Division of Intramural Research
- Eunice Kennedy Shriver
Options for accessing this content:
- If you are a society or association member and require assistance with obtaining online access instructions please contact our Journal Customer Services team.
- If your institution does not currently subscribe to this content, please recommend the title to your librarian.
- Login via other institutional login options http://onlinelibrary.wiley.com/login-options.
- You can purchase online access to this Article for a 24-hour period (price varies by title)
- If you already have a Wiley Online Library or Wiley InterScience user account: login above and proceed to purchase the article.
- New Users: Please register, then proceed to purchase the article.
Login via OpenAthens
Search for your institution's name below to login via Shibboleth.
Registered Users please login:
- Access your saved publications, articles and searches
- Manage your email alerts, orders and subscriptions
- Change your contact information, including your password
Please register to:
- Save publications, articles and searches
- Get email alerts
- Get all the benefits mentioned below!
Patients and/or caregivers may access this content for use in relation to their own personal healthcare or that of a family member only. Terms and conditions will apply.